The efficacy of talazoparib and other PARP inhibitors has been primarily reported in germline BRCA mutation carriers. New results establish germline mutations in PALB2, but not in other homologous recombination (HR) genes, as targets for PARP inhibitors in breast cancer, whereas the added predictive value of HR signatures remains uncertain.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial
Oncogene Open Access 09 November 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Farmer, H. et al. Nature 434, 917–921 (2005).
Robson, M. et al. N. Engl. J. Med. 377, 523–533 (2017).
Litton, J. K. et al. N. Engl. J. Med. 379, 753–763 (2018).
Stewart, M. D. et al. Oncologist 27, 167–174 (2022).
Tung, N. M. et al. J. Clin. Oncol. 38, 4274–4282 (2020).
Gruber, J. J. et al. Nat. Cancer https://doi.org/10.1038/s43018-022-00439-1 (2022).
Favero, F. et al. Ann. Oncol. 26, 64–70 (2015).
Alexandrov, L. B. et al. Nature 500, 415–421 (2013).
Condorelli, R. et al. Ann. Oncol. 30, 365–373 (2019).
Henry, N. L. et al. J. Clin. Oncol. https://doi.org/10.1200/jco.22.01063 (2022).
Chakravarty, D. et al. J. Clin. Oncol. https://doi.org/10.1200/jco.21.02767 (2022).
Eeckhoutte, A. et al. Bioinformatics 36, 3888–3889 (2020).
Lazard, T. et al. Preprint at bioRxiv https://doi.org/10.1101/2021.09.10.459734 (2021).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
F.-C.B. declares research grants, speaker and advisory board honoraria from Pfizer and Astra-Zeneca, and advisory board honoraria from GSK. F.C. declares no competing interests.
Rights and permissions
About this article
Cite this article
Coussy, F., Bidard, FC. Expanding biomarkers for PARP inhibitors. Nat Cancer 3, 1141–1143 (2022). https://doi.org/10.1038/s43018-022-00440-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-022-00440-8
